Neurocrine Biosciences announced the initiation of a Phase 1 clinical study for the compound NBI-1140675, a new VMAT2 inhibitor. This development could influence investor sentiment, though the ...

Neurocrine (NBIX) Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound NBI ...

Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees potential upside for Neurocrine shares with multiple ...

SAN DIEGO, March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability ...

IFP Advisors Inc raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC.

Oppenheimer Asset Management Inc. bought a new stake in LendingClub Co. (NYSE:LC – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities ...

Matt Abernethy, Chief Financial Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), a company currently valued at $11.4 billion with strong financial health according to InvestingPro analysis ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company specializing in neurological and endocrine-related disorders, finds itself at a critical juncture as it navigates a shifting ...

Analysts' ratings for Neurocrine Biosciences NBIX over the last quarter vary from bullish to bearish, as provided by 15 analysts. The table below offers a condensed view of their recent ratings ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company specializing in neurological and endocrine-related disorders, finds itself at a critical juncture as it navigates a shifting ...